Bibliographic information
GuidelineConsolidated guidelines on general HIV care and the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach
Year of Publication2013
Issuing InstitutionWHO
Recommendation
Maintained
Originally developed
dolutegravir (DTG) in combination with an optimized nucleoside reverse-transcriptase inhibitor backbone is recommended as the preferred second-line regimen for children with approved DTG dosing for whom non-DTG-based regimens are failing
Recommended in favor
Strong
Certainty of evidence
Moderate
Also Featured In
This recommendation also appears in the following guidelines:
Guideline
Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV
Year2018
InstitutionWHO